Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity

Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Bassam Mahboub, Abdul Wahid Ansari, Mohamad-Hani Temsah, Adel M. Zakri, Elaref Ratemi, Rifat Hamoudi, Qutayba Hamid, Rabih Halwani
ERJ Open Research 2021 7: 00984-2020; DOI: 10.1183/23120541.00984-2020
Fatemeh Saheb Sharif-Askari
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narjes Saheb Sharif-Askari
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swati Goel
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bassam Mahboub
2Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdul Wahid Ansari
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamad-Hani Temsah
3Immunology Research Lab, Dept of Pediatrics, College of Medicine, King Saud University, Sharjah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohamad-Hani Temsah
Adel M. Zakri
4Dept of Plant Production, Faculty of Agriculture and Food Sciences, King Saud University, Riyadh, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elaref Ratemi
5Dept of Chemical and Process Engineering Technology, Jubail Industrial College, Jubail Industrial City, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rifat Hamoudi
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
6Dept of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rifat Hamoudi
Qutayba Hamid
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
6Dept of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
7Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rabih Halwani
1Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
6Dept of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
8Dept of Pediatrics, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rabih Halwani
  • For correspondence: rhalwani@sharjah.ac.ae
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Gene expression of interleukin (IL)-19, IL-6 and IL-17 in bronchial biopsies from patients with asthma of different severity categories. The data are for bronchial biopsies from patients with severe asthma (n=42) and mild/moderate asthma (n=18) and healthy controls (n=13) from the U-BIOPRED Project and Australian Newcastle severe asthma cohorts (GSE147881). a) IL-19 gene expression was significantly increased in the lungs of patients with severe and mild/moderate asthma compared to healthy controls. b) IL-6 gene expression was significantly increased in the lungs of patients with severe asthma compared to healthy controls. c) There was a trend towards increased IL-17 gene expression in the lungs of patients with severe and mild/moderate asthma compared to healthy controls. d) IL-20R1 and IL-20R2 gene expression increased in the lungs of patients with severe and mild/moderate asthma compared to healthy controls. e) IL-20R1 and IL-20R2 gene expression increased in severe asthmatic bronchial fibroblasts compared to healthy bronchial fibroblasts. Treatment of these cells with 100 ng·mL−1 IL-19 increased IL-20R1 and IL-20R2 gene expression levels. Fold change presented relative to healthy controls. Two-way comparison was done using two-tailed t-test. ns: nonsignificant. *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Gene expression of interleukin (IL)-19, IL-6 and IL-17 in bronchial brushing, blood and sputum samples from patients with asthma of different severity categories. a–c) The data are for bronchial brushing from patients with severe asthma (n=38) and mild/moderate asthma (n=50) and healthy controls (n=20) from the SARP cohorts (GSE43696). a) IL-19 gene expression is significantly increased in the bronchial brushings from patients with severe asthma compared to healthy controls, and there is a trend towards increased IL-19 expression in bronchial brushings from patients with mild/moderate asthma compared to healthy controls. b) There was a trend towards increased IL-6 gene expression in bronchial brushing from patients with severe and mild/moderate asthma compared to healthy controls. c) No distinct pattern was found in IL-17 gene expression in bronchial brushings from patients with severe and mild/moderate asthma compared to healthy controls. d–f) The data are for peripheral blood mononuclear cells (PBMCs) (GSE132006) from patients with allergic asthma (n=5) and healthy controls (n=5). d) There was a trend towards increased IL-19 gene expression in PBMCs from patients with asthma compared to healthy controls. e) No distinct pattern was found in IL-6 gene expression in PBMCs from patients with asthma compared to healthy controls. f) No distinct pattern was found in IL-17 gene expression in PBMCs from patients with asthma compared to healthy controls. g–i) The data are for sputum (GSE137268) from patients with controlled (n=21) and uncontrolled (n=21) asthma. g) IL-19 gene expression was slightly increased in the sputum of patients with uncontrolled asthma compared those with controlled asthma. h) There was a trend towards increased IL-6 expression in the sputum of patients with uncontrolled asthma compared to those with controlled asthma. i) No distinct pattern was found for IL-17 expression in the sputum of patients with uncontrolled asthma compared to those with controlled asthma. Two-way comparison was done using two-tailed t-tests (GSE43696). Limma adjusted p<0.05 (GSE132006 and GSE137268). ns: nonsignificant. *: p<0.05; **: p<0.01.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Plasma and saliva interleukin (IL)-19, IL-6 and IL-17 levels in patients with asthma of different severity categories. The data are for samples from patients with severe asthma (n=18) and mild/moderate asthma (n=12) and healthy controls (n=6). a, b) IL-19 level was significantly increased in plasma (a) and saliva (b) of patients with severe asthma compared to mild/moderate asthma; the increase in IL-19 level was more pronounced in saliva than in plasma level. c, d) There was a trend towards increased plasma IL-6 level (c) in patients with severe asthma compared to mild/moderate asthma, and a significant increase in saliva IL-6 level (d) in patients with severe asthma compared to mild/moderate asthma. e, f) No distinct pattern was found in plasma IL-17 levels (e) in patients with severe asthma compared to mild/moderate asthma, but there was a trend towards increased saliva IL-17 levels (f) in patients with severe asthma compared to mild/moderate asthma. Two-way comparison was done using two-tailed t-test. ns: nonsignificant. *: p<0.05; ****: p<0.0001.

  • FIGURE 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4

    Plasma interleukin (IL)-19 levels in asthma patients on different treatment regimens. a) Gene expression level of IL-19 in bronchial biopsies from healthy, non-smoker, non-allergic male volunteers treated with placebo or inhaled budesonide (1600 μg). The data show no difference in IL-19 expression levels between the two groups. b) Gene expression level of IL-19 in the peripheral blood mononuclear cells (PBMCs) untreated or treated with dexamethasone (500 nM) for 24 h. The data show no difference in IL-19 expression level between the treated and untreated PBMCs. c) Azithromycin and omalizumab decreases IL-19 plasma level in severe asthma. The data show that treatment with these medications significantly decreased IL-19 plasma level in patients with severe asthma. Two-way comparison was done using two-tailed t-tests. ns: nonsignificant. ****: p<0.0001.

  • FIGURE 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5

    Gene expression of interleukin (IL)-10, IL-20 and IL-24 in bronchial biopsies from patients with asthma of different severity categories. The data are from U-BIOPRED Project and Australian Newcastle severe asthma cohorts (GSE147881). a) IL-10 gene expression was significantly decreased in the lungs of patients with severe asthma compared to healthy controls. b) There was a trend towards increased lung IL-20 expression in patients with mild/moderate asthma compared to healthy controls. c) IL-24 gene expression was significantly decreased in the lungs of patients with mild/moderate asthma compared to healthy controls. Two-way comparison was done using two-tailed t-tests. ns: nonsignificant. *: p<0.05; **: p<0.01.

Supplementary Materials

  • Figures
  • Supplementary Material

    Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

    Supplementary tables 00984-2020.SUPPLEMENT_TABLES

    Supplementary figures 00984-2020.SUPPLEMENT_FIGURES

PreviousNext
Back to top
Vol 7 Issue 3 Table of Contents
ERJ Open Research: 7 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity
Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Bassam Mahboub, Abdul Wahid Ansari, Mohamad-Hani Temsah, Adel M. Zakri, Elaref Ratemi, Rifat Hamoudi, Qutayba Hamid, Rabih Halwani
ERJ Open Research Jul 2021, 7 (3) 00984-2020; DOI: 10.1183/23120541.00984-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity
Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Bassam Mahboub, Abdul Wahid Ansari, Mohamad-Hani Temsah, Adel M. Zakri, Elaref Ratemi, Rifat Hamoudi, Qutayba Hamid, Rabih Halwani
ERJ Open Research Jul 2021, 7 (3) 00984-2020; DOI: 10.1183/23120541.00984-2020
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original research articles

  • Electronic cigarettes suppress neutrophil function
  • Mood disorder in idiopathic pulmonary fibrosis
  • Sinonasal disease among patients with PCD
Show more Original research articles

Asthma

  • Characteristics of severe asthma patients on biologics
  • SABINA Junior
  • Inhaled formoterol impairs aerobic exercise capacity
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society